sanofi-aventis
Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number 1 in Europe. The Group operates in more than 100 countries. Net sales reached 28.4 billion euros in 2006, of which 25.8 billion euros in pharmaceuticals and 2.5 billion euros in vaccines.
Sanofi Pasteur, the vaccines business of the sanofi-aventis Group, sold more than a billion doses of vaccine in 2006, making it possible to protect more than 500 million people across the globe, which is about 1.5 million per day. The company offers the broadest range of vaccines, providing protection against 20 bacterial and viral diseases.
Sanofi-aventis is present in 7 major therapeutic areas: Metabolic Disorders, Cardiovascular, Thrombosis, Central Nervous System, Oncology, Internal Medicine and Vaccines.
Top 15 Drugs
Drug | Therapeutic area | 2006 net sales (M €) |
Lovenox® | Thrombosis | 2,435 |
Plavix® | Thrombosis | 2,229 |
Stilnox® /Ambien® | Central Nervous System | 2,026 |
Taxotere® | Oncology | 1,752 |
Eloxatin® | Oncology | 1,693 |
Lantus® | Metabolism | 1,666 |
Copaxone® | Central Nervous System | 1,069 |
Aprovel® | Cardiovascular | 1,015 |
Tritace® | Cardiovascular | 977 |
|
Allegra®
|
Allergy
|
688
|
|
Amaryl®
|
Metabolism
|
451
|
|
Xatral®
|
Urology
|
353
|
|
Actonel®
|
Osteoporosis
|
351
|
|
Depakine®
|
Central Nervous System
|
301
|
|
Nasacort®
|
Allergy
|
283
|
Vaccines
|
Vaccines
|
2006 net sales (M €)
|
|
Polio/Whooping Cough/Hib Vaccines
|
633
|
|
Adult Booster Vaccines
|
337
|
|
Influenza Vaccines
|
835
|
|
Travel Vaccines
|
239
|
|
Meningitis/Pneumonia Vaccines
|
310
|
|
Other vaccines
|
179
|
|
TOTAL
|
2 533
|
Research & Development (R&D)
With a budget of 4.4 billion euros in 2006, the Group’s R&D portfolio includes 125 projects in development. Forty-six of those projects are in late-stage development phases - phase II b and III. R&D activities are located at 28 places on 3 continents.
Stock Market
The Group is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY), and is one of the largest market capitalizations in Paris.
|
|
|
